COCH (Envoy Medical) 1-Year Sharpe Ratio: -0.80 (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COCH Envoy Medical Inc COCH
6 GF Score
Price $0.71
GF Value $0.66
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Envoy Medical 1-Year Sharpe Ratio?

Envoy Medical COCH +1.01% 6 1-Year Sharpe Ratio is -0.80 as of Sep. 21, 2026. GuruFocus rates COCH with a GF Score™ of 6/100 and a GF Value™ of $0.66 (Fairly Valued). The stock has 8 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-21), Envoy Medical's 1-Year Sharpe Ratio is -0.80.

Envoy Medical  (NAS:COCH) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Envoy Medical 1-Year Sharpe Ratio Related Terms

COCH vs XTNT, POSC, MDAI: 1-Year Sharpe Ratio Comparison

For the Medical Devices subindustry, Envoy Medical's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Envoy Medical 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Envoy Medical's 1-Year Sharpe Ratio falls into.


COCH
6GF Score
Envoy Medical Inc COCH
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Envoy Medical 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.80 mean?
Envoy Medical (COCH) has a 1-Year Sharpe Ratio of -0.80 as of Sep. 21, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Envoy Medical and its competitors.
Is Envoy Medical's 1-Year Sharpe Ratio too high?
Envoy Medical's current 1-Year Sharpe Ratio is -0.80. Overall, Envoy Medical has a GF Score™ of 6/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's 1-Year Sharpe Ratio compare to XTNT and POSC?
Envoy Medical's 1-Year Sharpe Ratio of -0.80 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Envoy Medical and its competitors. Envoy Medical's current 1-Year Sharpe Ratio is -0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Fairly Valued. The stock's GF Value™ is $0.66, compared to a current price of $0.71 — trading 7.7% above its estimated fair value. The current 1-Year Sharpe Ratio is -0.80. Envoy Medical's overall GF Score™ is 6/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Envoy Medical (COCH), the current 1-Year Sharpe Ratio is -0.80 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Envoy Medical (COCH) Overvalued in 2026?

Based on GuruFocus' analysis, Envoy Medical stock appears to be overvalued. The current stock price of $0.71 is trading 7.7% above its estimated GF Value™ of $0.66. GuruFocus considers Envoy Medical to be Fairly Valued.

Key valuation signals for COCH:

  • 1-Year Sharpe Ratio: -0.80
  • GF Value™: $0.66 vs. price of $0.71 (7.7% above fair value)
  • GF Score™: 6/100 with 8 warning signs

No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Envoy Medical Business Description

Address 4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
6GF Score

Get the complete analysis for COCH

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price
$0.66
GF Value